The UK’s Voluntary Scheme for Branded Medicines Pricing, Access and Growth (VPAG) entered 2026 with a noticeably lower repayment rate of 14.5% for newer medicines, down from close to 23% in 2025. For many across the industry, this reduction feels like a stabilisation after a year of heightened concern about the UK’s commercial attractiveness.
VPAG, however, has not fundamentally changed. It remains a national budget control mechanism. If total NHS spending on eligible branded medicines grows beyond the agreed cap, companies repay a percentage of their UK sales. The percentage may fluctuate year to year, but the structure persists.
Most discussions stop at the headline rate. Yet the more meaningful shift lies not in the percentage itself, but in how it interacts with growth.
How the VPAG Repayment Mechanism Works
Mechanically, the calculation is simple. If eligible UK branded sales are £100 million and the repayment rate is 14.5%, £14.5 million is returned to the Government. Net retained revenue becomes £85.5 million.
The Growth Dynamic: Where VPAG Gets More Complex
The dynamic becomes more interesting when expansion occurs. Consider a portfolio generating £100 million in UK sales that grows to £120 million following a new indication launch or accelerated uptake. At 14.5%, the repayment rises to £17.4 million. Net retained revenue becomes £102.6 million.
The £20 million increase in sales translates into £17.1 million in retained revenue. The remaining £2.9 million effectively flows back through the repayment mechanism. At last year’s rate of 23%, that same £20 million growth would have yielded only £15.4 million in retained revenue.
This reframes VPAG from a static deduction into something closer to a growth-linked levy. The faster a portfolio expands, the larger the absolute repayment.
Which Therapy Areas Are Most Exposed
This matters particularly in therapy areas driving NHS expenditure growth. Obesity treatments, oncology innovations, advanced biologics and immunology assets often experience rapid uptake and high per-patient costs. These categories contribute materially to national spending growth and therefore to the repayment environment as a whole. Companies operating in such spaces may find that strong commercial performance proportionally increases repayment exposure.
By contrast, mature portfolios in slower-growth primary care areas may experience relatively stable repayment dynamics. The difference is not in the repayment rate applied, but in the scale and trajectory of revenue.
What This Means for UK Launch Planning
For mid-sized and emerging biotechnology companies concentrated around a single high-growth asset, this dynamic can be especially material. Repayment is applied to total eligible sales, but the marginal effect of expansion determines how much incremental growth is ultimately retained.
The 2026 rate reduction provides breathing room. It does not alter the structural reality that the UK has evolved into a capped-growth system where exposure scales with revenue.
In this environment, modelling the marginal economics of growth, not just the headline repayment rate – is becoming central to UK launch planning and portfolio strategy.
At GPI, we increasingly support companies in interpreting what policies like VPAG mean in practice for pricing strategy, launch planning and portfolio positioning in the UK market.
Understanding the true impact of VPAG requires modelling beyond the headline repayment rate. At GPI, we help pharmaceutical and biotech companies stress-test their UK revenue assumptions, model the marginal economics of growth under VPAG, and build launch strategies that account for the full commercial picture – not just the annual percentage.
